No Data
No Data
A Quick Look at Today's Ratings for Xencor(XNCR.US), With a Forecast Between $30 to $30
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Xencor (XNCR) and GeneDx Holdings (WGS)
Piper Sandler Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $30
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study Of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody For Treatment Of Inflammatory Bowel Disease
Express News | Xencor Inc - Xmab942 Well Tolerated in Single and Multiple Doses
Express News | Xencor Inc - Lead Selection for Xmab Tl1a X Il23P19 Program on Track for First-in-Human Study Start in 2026